The National Health Planning Commission gives policy suggestions, and then under the leadership of the provincial health planning commissions, centralized drug procurement at the provincial level is the focus of pharmaceutical companies. After the new medical reform, the National Medical Insurance Bureau will dominate the right to purchase drugs, consumables and equipment after its establishment. The Guiding Opinions clarify that the Health and Health Commission only has the right to supervise the purchase and use. The separation of purchase right and supervision right will change the situation of being a referee and an athlete in the past. It is conceivable that in the future, the Health and Health Commission will strengthen the supervision of drug procurement and use, and the guidance also requires the Health and Health Commission to shoulder the responsibility of "controlling the unreasonable increase of medical expenses". Therefore, the supervision of prescription review, key drugs and auxiliary drugs will be stricter, and rational drug use is the focus of supervision.